We’re looking forward to Nimbus Therapeutics’ #ASCO24 presentation of new positive data from their Phase 1/2 clinical trial of NDI-101150, a hematopoietic progenitor kinase 1 (HPK1) inhibitor in development for the treatment of advanced #solidtumors. More about the results here: https://bit.ly/3Kere2j
The #Nimbi team is looking forward to attending the American Society of Clinical Oncology (ASCO) Annual Meeting next week. Marcus Noel, M.D., will present new positive monotherapy data from a Phase 1/2 trial evaluating our investigational HPK1 inhibitor in the treatment of advanced solid tumors. https://lnkd.in/e7_RE_7A #ASCO24